Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30963525 | 0.90 | SMN1; SMN2 (0.50) | PREPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL818418 | 0.90 | SMN1; SMN2 (0.50) | PREPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL821085 | 0.90 | SMN1; SMN2 (0.50) | PREPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL29997431 | 0.89 | PSEN1 (0.49) | PREPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL29998404 | 0.89 | PSEN1 (0.49) | PREPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL23478108 | 0.89 | PSEN1 (0.49) | PREPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL29997793 | 0.89 | PSEN1 (0.49) | PREPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL25698137 | 0.89 | PSEN1 (0.49) | PREPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL819239 | 0.82 | SMN1; SMN2 (0.53) | PREPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL23485195 | 0.82 | SMN1; SMN2 (0.53) | PREPSMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270740-A1 | INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. | 2024-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270740-A1 | INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | CGAS, GMPS, PRKG1 | PREP 2401/4885SMN1; SMN2 1213/4885NPC1 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.